Captain T Cell's Triumph in Securing Seed Financing Round of €8.5 Million Marks a Milestone in Biotech Innovation
May 22, 2024, 3:32 pm
Captain T Cell
Total raised: $9.24M
Captain T Cell, a pioneering biotechnology company based in Schoenefeld/Berlin, Germany, has achieved a significant milestone by successfully closing a seed financing round totaling €8.5 million. This achievement was made possible through the support of prominent investors, including i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H, along with backing from the German Federal Ministry of Education and Research (BMBF) through its esteemed GO-Bio program.
The funds secured in this round will be instrumental in accelerating the development of a new generation of T cell therapies specifically designed to combat solid tumors. Captain T Cell's innovative approach focuses on enhancing the efficacy of TCR-T cells for solid tumors that are currently not effectively addressed by existing treatments. Through a combination of cutting-edge technologies, the company has developed TCR-T cells with enhanced persistence and the ability to navigate the challenging tumor microenvironment of difficult-to-treat solid tumors.
One of the key highlights of Captain T Cell's technology portfolio is its proprietary TCR-ALLO platform, which enables the development of off-the-shelf treatments for solid tumors. This versatile platform has shown promising results in preclinical in vivo models, demonstrating the potential to completely eradicate aggressive tumors. The company's commitment to advancing these novel therapies is underscored by the appointment of biotech veteran Jörn Aldag as Chairman of the Board of Directors.
Founded as a spin-off from the prestigious Max Delbrück Center in Berlin, Captain T Cell has garnered recognition for its dedication to advancing immuno-oncology research. The institute's support during the pre-seed phase, coupled with its ongoing partnership through technology transfer partner Ascenion, has been instrumental in the company's journey towards innovation and impact in the field of cancer therapeutics.
Dr. Felix Lorenz, CEO of Captain T Cell, expressed his enthusiasm for the successful financing round, emphasizing the company's commitment to bringing life-saving options to patients who are underserved by current treatments. The support from investors and the BMBF funding through the GO-Bio program will enable Captain T Cell to accelerate the progression of its lead candidate towards clinical trials and establish its TCR-ALLO platform as a frontrunner in off-the-shelf solid tumor therapeutics.
The endorsement from investors such as i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H reflects the confidence in Captain T Cell's scientific depth and management capabilities. The potential of the company's off-the-shelf approach holds promise for delivering cost-effective and widespread access to life-saving therapies, positioning Captain T Cell as a global leader in the development of novel oncology drugs.
In conclusion, Captain T Cell's successful seed financing round of €8.5 million signifies a significant step forward in the advancement of innovative T cell therapies for solid tumors. With a focus on efficacy-enhanced treatments and a commitment to addressing unmet medical needs, the company is poised to make a transformative impact in the fight against cancer.
The funds secured in this round will be instrumental in accelerating the development of a new generation of T cell therapies specifically designed to combat solid tumors. Captain T Cell's innovative approach focuses on enhancing the efficacy of TCR-T cells for solid tumors that are currently not effectively addressed by existing treatments. Through a combination of cutting-edge technologies, the company has developed TCR-T cells with enhanced persistence and the ability to navigate the challenging tumor microenvironment of difficult-to-treat solid tumors.
One of the key highlights of Captain T Cell's technology portfolio is its proprietary TCR-ALLO platform, which enables the development of off-the-shelf treatments for solid tumors. This versatile platform has shown promising results in preclinical in vivo models, demonstrating the potential to completely eradicate aggressive tumors. The company's commitment to advancing these novel therapies is underscored by the appointment of biotech veteran Jörn Aldag as Chairman of the Board of Directors.
Founded as a spin-off from the prestigious Max Delbrück Center in Berlin, Captain T Cell has garnered recognition for its dedication to advancing immuno-oncology research. The institute's support during the pre-seed phase, coupled with its ongoing partnership through technology transfer partner Ascenion, has been instrumental in the company's journey towards innovation and impact in the field of cancer therapeutics.
Dr. Felix Lorenz, CEO of Captain T Cell, expressed his enthusiasm for the successful financing round, emphasizing the company's commitment to bringing life-saving options to patients who are underserved by current treatments. The support from investors and the BMBF funding through the GO-Bio program will enable Captain T Cell to accelerate the progression of its lead candidate towards clinical trials and establish its TCR-ALLO platform as a frontrunner in off-the-shelf solid tumor therapeutics.
The endorsement from investors such as i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H reflects the confidence in Captain T Cell's scientific depth and management capabilities. The potential of the company's off-the-shelf approach holds promise for delivering cost-effective and widespread access to life-saving therapies, positioning Captain T Cell as a global leader in the development of novel oncology drugs.
In conclusion, Captain T Cell's successful seed financing round of €8.5 million signifies a significant step forward in the advancement of innovative T cell therapies for solid tumors. With a focus on efficacy-enhanced treatments and a commitment to addressing unmet medical needs, the company is poised to make a transformative impact in the fight against cancer.